PRIMEX-PHARMACEUTICALS
3.5.2017 10:41:04 CEST | Business Wire | Press release
Jostein Davidsen brings over 30 years of experience from the international pharmaceutical industry, most recently serving as CEO of Acino Pharmaceuticals in Switzerland.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170503005582/en/
Mr. Davidsen was the founder of Nycomed Russia-CIS which he built up to be one of the leading pharmaceutical companies in the region, until being sold to Takeda Pharmaceuticals in 2011. Davidsen then became Corporate Officer and Head of the Emerging Markets at Takeda in Zurich. He was named the world's second most influential pharma-industry leader in Emerging Markets by pharma news service Scrip.
Angelo Colombo has 25 years of experience from the pharmaceutical sector. Recently, he was Managing Director at Corden Pharma Spa with extensive experience in the manufacture of pharmaceuticals, especially injectables.
Previously, Mr. Colombo was the Nerviano site leader for Pfizer, one of the largest pharmaceutical R&D centers for oncology in Europe. He was also General Manager at Pierrel, a leading dental anaesthetic manufacturer. In these roles, Colombo obtained FDA and EMEA approvals at all sites, built a new injectable department with the highest technology standards and developed new formulations.
Panu Paappanen, Chairman of the Board, commented: "With these appointments the board gains senior pharma executives to strengthen the strategic expertise in growing our global pharmaceutical business.”
Kari Sarvanto, CEO and Co-Founder of Primex, added: “I am delighted that we can attract experienced pharmaceutical professionals to our board, at a time when Primex is progressing to a new and exciting stage of strong and sustainable growth.”
About Primex Pharmaceuticals:
Primex Pharmaceuticals aims to become the leading global innovative anaesthesia company, and to expand in paediatric and orphan pharmaceuticals.
A portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer to a novel oral solution for paediatric procedural sedation, is helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals continues to identify and acquire new medications that complete the ‘Triad of Anaesthesia’.
Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170503005582/en/
Contact:
Primex Pharmaceuticals
Mr. Kari Sarvanto, Group CEO
Mobile:
+41 796 162 694
Email: kari.sarvanto@primexintl.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom